Jun.03.2026
R & D
Bristol Myers Squibb Announces OPDIVO® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
This material is intended to notify the press release issued on June 1 (local time) by Bristol Myers Squibb, our license partner for OPDIVO.
Please click https://www.bms.com/media/press-releases.html for the original press release.